2. Signaling Pathways
  3. GPCR/G Protein
    Neuronal Signaling
  4. Cannabinoid Receptor

Cannabinoid Receptor

Cannabinoid Receptor

Cannabinoid Receptor

Related Products

PDF 1.36 MB

Cannabinoid receptors are currently classified into three groups: central (CB1), peripheral (CB2) and GPR55, all of which are G-protein-coupled. CB1 receptors are primarily located at central and peripheral nerve terminals. CB2 receptors are predominantly expressed in non-neuronal tissues, particularly immune cells, where they modulate cytokine release and cell migration. Recent reports have suggested that CB2 receptors may also be expressed in the CNS. GPR55 receptors are non-CB1/CB2 receptors that exhibit affinity for endogenous, plant and synthetic cannabinoids. Endogenous ligands for cannabinoid receptors have been discovered, including anandamide and 2-arachidonylglycerol.

Cannabinoid Receptor Isoform Specific Products:

Cannabinoid Receptor Isoform Comparison
Cat. No. Product Name Effect Purity Chemical Structure
  • HY-10863S
    Anandamide-d8
    		Agonist 99.90%
    Anandamide-d8 is a deuterated labeled Anandamide. Anandamide is an endocannabinoid. Anandamide modulates both neuronal and immune functions through two protein-coupled cannabinoid receptors (CB1 and CB2). Anandamide can activate numerous other receptors like PPARS, TRPV1, and GPR18/GPR55. Anandamide also has potential anti-fungal and anti-inflammatory activities. Anandamide can be used for the research of Alzheimer’s disease (AD) and ulcerative colitis.
    Anandamide-d<sub>8</sub>
  • HY-172587
    CB1R Allosteric modulator 5
    		Modulator 98.35%
    CB1R Allosteric modulator 5 (compound 3) is a selective, and blood-brain barrier (BBB) permeable Cannabinoid receptor type 1 allosteric modulator with a pIC50 of 6.89. CB1R Allosteric modulator 5 attenuates both cocaine-seeking behavior specific to cue-induced reinstatement and cocaine-induced behavioral sensitization without altering locomotor activity.
    CB1R Allosteric modulator 5
  • HY-W775306
    Cannabidivarinic acid
    		Ligand 99.67%
    Cannabidivarinic acid (CBDVA), the carboxylic acid precursor of Cannabidivarin(CBDV), is a non-psychoactive cannabinoid found in Cannabis with anti-inflammatory properties.
    Cannabidivarinic acid
  • HY-146134
    PGN36
    		Antagonist 99.74%
    PGN36 is a selective cannabinoid CB2 receptor (CB2R) antagonist with Kis of 0.09 µM and >40 µM for CB2R and CB1R, respectively. PGN36 abolishes the increase in collagen type I gene expression by the inducer of bone activity. PGN36 is able to cross the blood-brain barrier. PGN36 can be used for the study of frontotemporal dementia (FTD).
    PGN36
  • HY-15420
    BML-190
    		Agonist 99.53%
    BML-190(IMMA) is a potent and selective CB2 receptor ligand (Ki values are 435 nM and > 2 μM for CB2 and CB1 respectively).
    BML-190
  • HY-12761
    A-836339
    		Agonist 99.84%
    A-836339 is a selective CB2 receptor agonist, with Ki values of 0.4 nM and 0.8 nM in humans and rats, respectively. A-836339 exhibits multiple effects such as analgesia, gastric protection, anti-inflammation, and antioxidant activity. A-836339 produces antinociceptive and analgesic activities by activating CB2 receptors in the dorsal root ganglia and spinal cord. A-836339 can also exert gastric protective effects through anti-inflammatory mechanisms (reducing TNF-α and IL-1β) and antioxidant mechanisms (enhancing the activities of CAT and SOD, and reducing H2O2). Radioactively labeled A-836339 can serve as a CB2-specific radioligand for autoradiography and PET imaging. A-836339 can be used in research on inflammatory pain, neuropathic pain, gastric ulcers, cerebral ischemia, etc.
    A-836339
  • HY-148176
    ANEB-001
    		Inhibitor 99.73%
    ANEB-001 is an orally active CB1 inhibitor, can be used to research acute cannabinoid intoxication.
    ANEB-001
  • HY-113689
    GAT211
    		Agonist 99.98%
    GAT211 is a cannabinoid 1 receptor (CB1R) positive allosteric modulator (PAM). GAT211 activates cAMP and β-arrestin2 with EC50 values of 260 nM and 650 nM, respectively. GAT211 inhibits GAT211 can be used for neuropathic and/or inflammatory pain research.
    GAT211
  • HY-113070
    Dihomo-γ-Linolenoyl Ethanolamide
    		Agonist 99.9%
    Dihomo-γ-Linolenoyl Ethanolamide, an endocannabinoid, is a cannabinoid (CB) receptor agonist with Kis of 857 nM and 598 nM for human recombinant CB1 and CB2 receptors, respectively.
    Dihomo-γ-Linolenoyl Ethanolamide
  • HY-135882
    OMDM-6
    		Agonist
    OMDM-6 is a hybrid agonist of vanilloid receptor type 1 (VR1, TRPV1) (EC50=75 nM) and cannabinoid receptor type 1 (CB1) (Ki=3.2 μM). OMDM-6 inhibits anandamide cellular uptake (ACU) with a Ki of 7.0 μM.
    OMDM-6
  • HY-135419
    CB2 modulator 1
    		Modulator 99.75%
    CB2 modulator 1 (compound 130) is a potent CB2 modulator. CB2 modulator 1 has the potential for immunedisorders, inflammation, osteoporosis, renal ischemia.
    CB2 modulator 1
  • HY-124283A
    LEI-101
    		Agonist 99.35%
    LEI-101 is a potent, selective, and orally bioavailable cannabinoid CB2 receptor agonist, with a pEC50 of 8 for hCB2, and a pKi of less than 4 for hERG. LEI-101 is ~100-fold more potent in binding to CB2 receptors than to CB1 receptors.
    LEI-101
  • HY-148940
    Docosahexaenoyl glycerol
    		≥99.0%
    Docosahexaenoyl glycerol is an analog of endocannabinoid, which stimulates the glucose uptake and exhibits anti-inflammatory efficacy.
    Docosahexaenoyl glycerol
  • HY-132217
    CB2 receptor agonist 2
    		Agonist 99.0%
    CB2 receptor agonist 2 is a potent and selective agonist for the CB2 (cannabinoid type 2) receptor with a Ki of 8.5 nM. CB2 receptor agonist 2 has high affinity and selectivity for CB2.
    CB2 receptor agonist 2
  • HY-125111
    PSB-SB-487
    		Modulator 98.01%
    PSB-SB-487 is a potent GPR55 antagonist and CB2 agonist with an IC50 value of 0.113 µM for GPR55, and a Ki value of 0.292 µM for human CB2. PSB-SB-487 can be used for researching diabetes, Parkinson’s disease, neuropathic pain, and cancer.
    PSB-SB-487
  • HY-10013A
    Taranabant racemate
    		Antagonist 99.84%
    Taranabant racemate (MK-0364 racemate) is an antagonist and/or inverse agonist of the Cannabinoid-1 (CB1) receptor extracted from patent WO 2004048317 A1.
    Taranabant racemate
  • HY-113591
    CB2 receptor agonist 10
    		Activator ≥99.0%
    CB2 receptor agonist 10 is a CB2 receptor agonist with a Ki of 3.7 nM for hCB2, a Ki of 110 nM for hCB1, and an EC50 of 0.52 nM for hCB2.
    CB2 receptor agonist 10
  • HY-134173
    Arachidonoyl ethanolamide phosphate
    		Agonist 99.9%
    Arachidonoyl ethanolamide phosphate, an endocannabinoid, is an endogenous ligand for cannabinoid receptors in the central nervous system (CB1 subtype) and peripheral immune cells (CB2 subtype).
    Arachidonoyl ethanolamide phosphate
  • HY-122964
    URB447
    		Antagonist 99.5%
    URB447 is a peripherally restricted CB1 cannabinoid antagonist (IC50: 313 nM and 41 nM for rat CB1 and human CB2 receptor respectively ). URB447 lowers food intake and body-weight gain in mice without entering the brain or antagonizing central CB1-dependent responses. URB447 can be used for research of obesity.
    URB447
  • HY-145153
    S-777469
    		Agonist 98.19%
    S-777469 is a selective and orally available cannabinoid type 2 receptor (CB2) agonist with a Ki of 36 nM. S-777469 significantly suppresses compound 48/80-induced scratching behavior in mice in a dose-dependent manner. S-777469 produces its antipruritic effects by inhibiting itch signal transmission through CB2 agonism.
    S-777469
Cat. No. Product Name / Synonyms Application Reactivity
Cannabinoid Receptor Isoform Comparison

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform together.

Please try each isoform separately.